Stocks · Health care · Biological Products, (No Diagnostic Substances)

Tarsus Pharmaceuticals, Inc.

TARS Clue Score56
United States Fiscal year ends December CIK 0001819790 Results filed 3 Nov 2026

What the insiders did Net selling

Insider
Date
Role
Action
Shares
Price
Amount
Jeffrey S Farrow
16 Jun 2026
See Remarks
Sell
14,396
$60.95
$877.44K
Bobak R. Azamian
19 Mar 2026
President/CEO and Board Chair
Sell
11,964
$67.00
$801.59K
Jeffrey S Farrow
19 Mar 2026
See Remarks
Sell
2,186
$67.00
$146.46K
Elizabeth Yeu Lin
19 Mar 2026
Chief Medical Officer
Sell
390
$67.00
$26.13K
Aziz Mottiwala
19 Mar 2026
Chief Commercial Officer
Sell
4,440
$67.00
$297.48K
Seshadri Neervannan
19 Mar 2026
Chief Operating Officer
Sell
4,589
$67.00
$307.46K
Bryan Wahl
19 Mar 2026
General Counsel
Sell
4,231
$67.00
$283.48K
Dianne C. Whitfield
19 Mar 2026
Chief Human Resources Officer
Sell
4,174
$67.00
$279.66K
Bobak R. Azamian
18 Mar 2026
President/CEO and Board Chair
Sell
11,667
$68.71
$801.64K
Jeffrey S Farrow
18 Mar 2026
See Remarks
Sell
2,133
$68.71
$146.56K
Elizabeth Yeu Lin
18 Mar 2026
Chief Medical Officer
Sell
379
$68.71
$26.04K
Aziz Mottiwala
18 Mar 2026
Chief Commercial Officer
Sell
4,330
$68.71
$297.51K
Seshadri Neervannan
18 Mar 2026
Chief Operating Officer
Sell
3,610
$68.71
$248.04K
Bryan Wahl
18 Mar 2026
General Counsel
Sell
4,125
$68.71
$283.43K
Dianne C. Whitfield
18 Mar 2026
Chief Human Resources Officer
Sell
4,071
$68.71
$279.72K
Bobak R. Azamian
17 Mar 2026
President/CEO and Board Chair
Sell
10,972
$69.42
$761.68K
Jeffrey S Farrow
17 Mar 2026
See Remarks
Sell
2,111
$69.42
$146.55K
Elizabeth Yeu Lin
17 Mar 2026
Chief Medical Officer
Sell
375
$69.42
$26.03K
Aziz Mottiwala
17 Mar 2026
Chief Commercial Officer
Sell
4,286
$69.42
$297.53K
Seshadri Neervannan
17 Mar 2026
Chief Operating Officer
Sell
3,125
$69.42
$216.94K
Bryan Wahl
17 Mar 2026
General Counsel
Sell
4,084
$69.42
$283.51K
Dianne C. Whitfield
17 Mar 2026
Chief Human Resources Officer
Sell
4,029
$69.42
$279.69K
Elizabeth Yeu Lin
16 Dec 2025
Chief Medical Officer
Sell
2,078
$79.50
$165.20K

What was left out

Form 4 filings counted 60
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 33
Sales straight out of an exercise 3
Sales at will 23
Transactions with no price 0
Shares from compensation/vesting 292,795
History held since 20 Oct 2020